Sugi Predict

Sugi Predict / Compounds / Folic Acid

Folic Acid

Folic Acid

SCHEMBL454201

NCCNCCN.Nc1nc2ncc(CNc3ccc(C(=O)NC(CCC(=O)O)C(=O)O)cc3)nc2c(=O)[nH]1

nearest known ligand 0.89

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ TYMS P04818 4/20 0.89
▸ KDM4E B2RXH2 1/20 0.89
▸ MEN1 O00255 1/20 0.89
▸ ALDH1A1 P00352 1/20 0.89
▸ POLB P06746 1/20 0.89
▸ GAA P10253 1/20 0.89
▸ AKR1B1 P15121 1/20 0.89
▸ HPGD P15428 1/20 0.89
▸ TSHR P16473 1/20 0.89
▸ PTGS2 P35354 1/20 0.89
▸ KMT2A Q03164 1/20 0.89
▸ HSD17B10 Q99714 1/20 0.89
▸ TDP1 Q9NUW8 1/20 0.89
▸ ADORA3 P0DMS8 1/20 0.66
▸ DHFR P00374 6/20 0.61
▸ GART P22102 4/20 0.61
▸ ATIC P31939 4/20 0.61
▸ MTHFD1 P11586 1/20 0.52
▸ MTHFD2 P13995 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Folic Acid SCHEMBL451956 0.95 TYMS (0.95) TYMSKDM4EMEN1ALDH1A1POLB
Folic Acid SCHEMBL29441959 0.94 TYMS (1.00) TYMSKDM4EMEN1ALDH1A1POLB
Folic Acid SCHEMBL29357550 0.94 TYMS (1.00) TYMSKDM4EMEN1ALDH1A1POLB
Folic Acid SCHEMBL29388311 0.94 TYMS (1.00) TYMSKDM4EMEN1ALDH1A1POLB
Folic Acid SCHEMBL403054 0.94 TYMS (1.00) TYMSKDM4EMEN1ALDH1A1POLB
Folic Acid SCHEMBL16492117 0.94 TYMS (1.00) TYMSKDM4EMEN1ALDH1A1POLB
Folic Acid SCHEMBL3877 0.94 TYMS (1.00) TYMSKDM4EMEN1ALDH1A1POLB
Folic Acid SCHEMBL332170 0.94 TYMS (1.00) TYMSKDM4EMEN1ALDH1A1POLB
Folic Acid SCHEMBL248712 0.94 TYMS (1.00) TYMSKDM4EMEN1ALDH1A1POLB
Folic Acid SCHEMBL29624885 0.94 TYMS (1.00) TYMSKDM4EMEN1ALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190216934-A9 Vitamin-Receptor Binding Drug Delivery Conjugates ENDOCYTE INC (US) 2019-07-18 — — US disclosed
US-20190105399-A1 Vitamin-Receptor Binding Drug Delivery Conjugates ENDOCYTE INC (US) 2019-04-11 — — US disclosed
US-20160220694-A1 Vitamin-Receptor Binding Drug Delivery Conjugates ENDOCYTE INC (US) 2016-08-04 — — US disclosed
US-20140058063-A1 VITAMIN RECEPTOR BINDING DRUG DELIVERY CONJUGATES ENDOCYTE, INC. (US) 2014-02-27 — — US disclosed
EP-2529758-A2 Vitamin receptor binding drug delivery conjugates Endocyte, Inc. (US) 2012-12-05 — — EP disclosed
EP-2517730-A2 Vitamin receptor binding drug delivery conjugates Endocyte, Inc. (US) 2012-10-31 — — EP disclosed
EP-2517729-A2 Vitamin receptor binding drug delivery conjugates Endocyte, Inc. (US) 2012-10-31 — — EP disclosed
EP-1592457-B1 FOLATE-VINBLASTINE CONJUGATE AS MEDICAMENT ENDOCYTE INC (US) 2012-07-25 — — EP disclosed
US-20120065149-A1 Vitamin receptor binding drug delivery conjugates VLAHOV IONTCHO R (US) 2012-03-15 — — US disclosed
US-8105568-B2 Vitamin receptor binding drug delivery conjugates ENDOCYTE, INC. (US) 2012-01-31 — — US disclosed
US-20100004276-A1 VITAMIN RECEPTOR BINDING DRUG DELIVERY CONJUGATES VLAHOV IONTCHO R 2010-01-07 — — US disclosed
US-7601332-B2 Minimized toxicity; eliminating pathogenic cell populations; synthesis; claimed intermediates ENDOCYTE, INC. (US) 2009-10-13 — — US disclosed
EP-1592457-A2 VITAMIN RECEPTOR BINDING DRUG DELIVERY CONJUGATES Endocyte, Inc. (US) 2005-11-09 — — EP disclosed
US-20050002942-A1 Minimized toxicity; eliminating pathogenic cell populations; synthesis; claimed intermediates ENDOCYTE, INC. 2005-01-06 — — US disclosed
WO-2004069159-A2 VITAMIN RECEPTOR BINDING DRUG DELIVERY CONJUGATES ENDOCYTE, INC. (US) 2004-08-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004276-A1 VITAMIN RECEPTOR BINDING DRUG DELIVERY CONJUGATES VDR, CYP2R1, CYP24A1 TYMS 1226/4885KDM4E 2700/4885MEN1 3425/4885
US-20050002942-A1 Minimized toxicity; eliminating pathogenic cell populations; synthesis; claimed intermediates VDR, CYP2R1, CYP24A1 TYMS 785/4885KDM4E 3274/4885MEN1 2876/4885
US-20120065149-A1 Vitamin receptor binding drug delivery conjugates VDR, CYP2R1, CYP24A1 TYMS 1226/4885KDM4E 2700/4885MEN1 3425/4885
US-20160220694-A1 Vitamin-Receptor Binding Drug Delivery Conjugates VDR, CYP2R1, CYP24A1 TYMS 1343/4885KDM4E 2503/4885MEN1 3249/4885
US-20140058063-A1 VITAMIN RECEPTOR BINDING DRUG DELIVERY CONJUGATES VDR, CYP2R1, CYP24A1 TYMS 1226/4885KDM4E 2700/4885MEN1 3425/4885
US-20190216934-A9 Vitamin-Receptor Binding Drug Delivery Conjugates VDR, CYP2R1, CYP24A1 TYMS 1343/4885KDM4E 2503/4885MEN1 3249/4885
US-20190105399-A1 Vitamin-Receptor Binding Drug Delivery Conjugates VDR, CYP2R1, CYP24A1 TYMS 1343/4885KDM4E 2503/4885MEN1 3249/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.